Supplementary Table 1. Frequency of local and systemic immediate adverse events by dose and age group.

	Dose 1 (n=963)	Dose 2 (n=624)
	Pa	ain
3-11 years	33 (3.8)	9 (1.7)
12-17 years	2 (2.2)	7 (8.2)
	Red	ness
3-11 years	20 (2.3)	3 (0.6)
12-17 years	0	0
	Indur	ation
3-11 years	5 (0.6)	0
12-17 years	1 (1.1)	0
	Pru	ritus
3-11 years	2 (0.2)	0
12-17 years	0	1 (1.2)
	Swe	lling
3-11 years	0	0
12-17 years	1 (1.1)	0
	Ot	her
3-11 years	1 (0.1)	1 (0.2)
12-17 years	0	0

Frequency of local immediate adverse events by dose and age group.

Frequency of systemic immediate adverse events by	y dose and age group.

	Headache	
3-11 years	6 (0.7)	1 (0.2)
12-17 years	2 (2.2)	1 (1.2)
	Fatigue	
3-11 years	4 (0.5)	1 (0.2)
12-17 years	0	0

	Muse	cle pain
3-11 years	1 (0.1)	0
12-17 years	0	1 (1.2)
	Na	ausea
3-11 years	1 (0.1)	0
12-17 years	0	0
		kin or
	mucosa	abnormality
3-11 years	0	0
12-17 years	0	1* (1.2)

\* Generalized pruritus, without rash or other symptoms, mild and self-limited

- Total volunteers for first dose (n=963): 3-11 years (n=873) and 12-17 years (n=90)
- Total volunteers for second dose (n=624): 3-11 years (n=539) and 12-17 years (n=85)
- •